Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Respiratory syncytial virus infection: from biology to therapy: a perspective.

Mohapatra SS, Lockey RF.

World Allergy Organ J. 2008 Feb;1(2):21-8. doi: 10.1097/WOX.0b013e31816549a2.

2.

Biological challenges and technological opportunities for respiratory syncytial virus vaccine development.

Graham BS.

Immunol Rev. 2011 Jan;239(1):149-66. doi: 10.1111/j.1600-065X.2010.00972.x. Review.

3.

Impairment of T cell immunity by the respiratory syncytial virus: targeting virulence mechanisms for therapy and prophylaxis.

González PA, Bueno SM, Riedel CA, Kalergis AM.

Curr Med Chem. 2009;16(34):4609-25. Review.

PMID:
19903147
4.

Host proteome correlates of vaccine-mediated enhanced disease in a mouse model of respiratory syncytial virus infection.

van Diepen A, Brand HK, de Waal L, Bijl M, Jong VL, Kuiken T, van Amerongen G, van den Ham HJ, Eijkemans MJ, Osterhaus AD, Hermans PW, Andeweg AC.

J Virol. 2015 May;89(9):5022-31. doi: 10.1128/JVI.03630-14. Epub 2015 Feb 18.

5.

Respiratory syncytial virus bronchiolitis : current and future strategies for treatment and prophylaxis.

Chávez-Bueno S, Mejías A, Welliver RC.

Treat Respir Med. 2006;5(6):483-94.

PMID:
17154675
6.

Mucosal vaccines against respiratory syncytial virus.

Yang K, Varga SM.

Curr Opin Virol. 2014 Jun;6:78-84. doi: 10.1016/j.coviro.2014.03.009. Epub 2014 Apr 29. Review.

8.

Clinical and epidemiologic features of respiratory syncytial virus.

Hall CB, Simőes EA, Anderson LJ.

Curr Top Microbiol Immunol. 2013;372:39-57. doi: 10.1007/978-3-642-38919-1_2.

PMID:
24362683
9.

Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats.

Kamphuis T, Shafique M, Meijerhof T, Stegmann T, Wilschut J, de Haan A.

Vaccine. 2013 Apr 19;31(17):2169-76. doi: 10.1016/j.vaccine.2013.02.043. Epub 2013 Mar 13.

PMID:
23499594
10.

Recent advances in the development of subunit-based RSV vaccines.

Jaberolansar N, Toth I, Young PR, Skwarczynski M.

Expert Rev Vaccines. 2016;15(1):53-68. doi: 10.1586/14760584.2016.1105134. Epub 2015 Oct 27. Review.

PMID:
26506139
11.

The host response and molecular pathogenesis associated with respiratory syncytial virus infection.

Oshansky CM, Zhang W, Moore E, Tripp RA.

Future Microbiol. 2009 Apr;4(3):279-97. doi: 10.2217/fmb.09.1. Review.

12.

A number-needed-to-treat analysis of the use of respiratory syncytial virus immune globulin to prevent hospitalization.

Robbins JM, Tilford JM, Jacobs RF, Wheeler JG, Gillaspy SR, Schutze GE.

Arch Pediatr Adolesc Med. 1998 Apr;152(4):358-66. Erratum in: Arch Pediatr Adolesc Med 1998 Jun;152(6):577.

PMID:
9559712
13.

Induction and Antagonism of Antiviral Responses in Respiratory Syncytial Virus-Infected Pediatric Airway Epithelium.

Villenave R, Broadbent L, Douglas I, Lyons JD, Coyle PV, Teng MN, Tripp RA, Heaney LG, Shields MD, Power UF.

J Virol. 2015 Dec;89(24):12309-18. doi: 10.1128/JVI.02119-15. Epub 2015 Sep 30.

14.

Intranasal administration of maleic anhydride-modified human serum albumin for pre-exposure prophylaxis of respiratory syncytial virus infection.

Sun Z, Wang Q, Jia R, Xia S, Li Y, Liu Q, Xu W, Xu J, Du L, Lu L, Jiang S.

Viruses. 2015 Feb 16;7(2):798-819. doi: 10.3390/v7020798.

16.

Respiratory syncytial virus regulates human microRNAs by using mechanisms involving beta interferon and NF-κB.

Thornburg NJ, Hayward SL, Crowe JE Jr.

MBio. 2012 Dec 18;3(6). pii: e00220-12. doi: 10.1128/mBio.00220-12.

17.

A respiratory syncytial virus (RSV) vaccine based on parainfluenza virus 5 (PIV5).

Phan SI, Chen Z, Xu P, Li Z, Gao X, Foster SL, Teng MN, Tripp RA, Sakamoto K, He B.

Vaccine. 2014 May 23;32(25):3050-7. doi: 10.1016/j.vaccine.2014.03.049. Epub 2014 Apr 8.

18.

A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without Th2 associated vaccine-enhanced disease.

Lindell DM, Morris SB, White MP, Kallal LE, Lundy PK, Hamouda T, Baker JR Jr, Lukacs NW.

PLoS One. 2011;6(7):e21823. doi: 10.1371/journal.pone.0021823. Epub 2011 Jul 15.

19.

Respiratory syncytial virus: immunopathology and control.

Zhang W, Lockey RF, Mohapatra SS.

Expert Rev Clin Immunol. 2006 Jan;2(1):169-79. doi: 10.1586/1744666X.2.1.169.

PMID:
20477096
20.

Respiratory syncytial virus entry inhibitors targeting the F protein.

Sun Z, Pan Y, Jiang S, Lu L.

Viruses. 2013 Jan 16;5(1):211-25. doi: 10.3390/v5010211. Review.

Supplemental Content

Support Center